View Future GrowthOptimind Pharma 과거 순이익 실적과거 기준 점검 0/6Optimind Pharma은 연평균 45.5%의 비율로 수입이 증가해 온 반면, Healthcare 산업은 연평균 30.2%의 비율로 증가했습니다. 매출은 연평균 11.3%의 비율로 증가했습니다.핵심 정보45.54%순이익 성장률53.36%주당순이익(EPS) 성장률Healthcare 산업 성장률-6.74%매출 성장률11.28%자기자본이익률n/a순이익률-37.80%최근 순이익 업데이트31 Aug 2025최근 과거 실적 업데이트Reported Earnings • Jul 31First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$35.7k (up 123% from 1Q 2025). Net loss: CA$294 (loss narrowed 100% from 1Q 2025).Reported Earnings • Jun 30Full year 2025 earnings released: CA$0.002 loss per share (vs CA$0.014 loss in FY 2024)Full year 2025 results: CA$0.002 loss per share (improved from CA$0.014 loss in FY 2024). Revenue: CA$118.4k (down 3.7% from FY 2024). Net loss: CA$215.8k (loss narrowed 85% from FY 2024).Reported Earnings • Jan 31Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: EPS: CA$0 (improved from CA$0.001 loss in 3Q 2024). Revenue: CA$26.6k (flat on 3Q 2024). Net loss: CA$9.0k (loss narrowed 91% from 3Q 2024).Reported Earnings • Nov 01Second quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 2Q 2024)Second quarter 2025 results: CA$0.001 loss per share (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$41.1k (up 50% from 2Q 2024). Net loss: CA$82.6k (loss narrowed 55% from 2Q 2024).Reported Earnings • Aug 01First quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 1Q 2024)First quarter 2025 results: CA$0.001 loss per share (improved from CA$0.004 loss in 1Q 2024). Revenue: CA$16.0k (down 61% from 1Q 2024). Net loss: CA$97.5k (loss narrowed 76% from 1Q 2024).Reported Earnings • Jul 01Full year 2024 earnings released: CA$0.014 loss per share (vs CA$0.038 loss in FY 2023)Full year 2024 results: CA$0.014 loss per share (improved from CA$0.038 loss in FY 2023). Revenue: CA$123.0k (down 28% from FY 2023). Net loss: CA$1.40m (loss narrowed 55% from FY 2023).모든 업데이트 보기Recent updates공시 • Sep 09Optimind Pharma Corp. announced that it expects to receive CAD 1.2 million in fundingOptimind Pharma Corp announced a private placement to issue 12,000,000 subscription receipts at an issue price of CAD 0.10 for the proceeds of CAD 1,200,000 on September 8, 2025. Finder's fees may be paid.Reported Earnings • Jul 31First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$35.7k (up 123% from 1Q 2025). Net loss: CA$294 (loss narrowed 100% from 1Q 2025).New Risk • Jul 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$310k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$310k free cash flow). Shares are highly illiquid. Negative equity (-CA$69k). Revenue is less than US$1m (CA$138k revenue, or US$100k). Market cap is less than US$10m (CA$515.7k market cap, or US$372.5k).Reported Earnings • Jun 30Full year 2025 earnings released: CA$0.002 loss per share (vs CA$0.014 loss in FY 2024)Full year 2025 results: CA$0.002 loss per share (improved from CA$0.014 loss in FY 2024). Revenue: CA$118.4k (down 3.7% from FY 2024). Net loss: CA$215.8k (loss narrowed 85% from FY 2024).Reported Earnings • Jan 31Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: EPS: CA$0 (improved from CA$0.001 loss in 3Q 2024). Revenue: CA$26.6k (flat on 3Q 2024). Net loss: CA$9.0k (loss narrowed 91% from 3Q 2024).Reported Earnings • Nov 01Second quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 2Q 2024)Second quarter 2025 results: CA$0.001 loss per share (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$41.1k (up 50% from 2Q 2024). Net loss: CA$82.6k (loss narrowed 55% from 2Q 2024).Reported Earnings • Aug 01First quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 1Q 2024)First quarter 2025 results: CA$0.001 loss per share (improved from CA$0.004 loss in 1Q 2024). Revenue: CA$16.0k (down 61% from 1Q 2024). Net loss: CA$97.5k (loss narrowed 76% from 1Q 2024).공시 • Jul 05Optimind Pharma Corp. announced that it expects to receive CAD 0.5 million in fundingOptimind Pharma Corp. announced a private placement to issue 10,000,000 common shares at a price of CAD 0.05 per share for gross proceeds of up to CAD 500,000 on July 3, 2024. All securities issued in connection with the private placement will be subject to a statutory hold period expiring four months and one day from the date of issuance of the securities.Reported Earnings • Jul 01Full year 2024 earnings released: CA$0.014 loss per share (vs CA$0.038 loss in FY 2023)Full year 2024 results: CA$0.014 loss per share (improved from CA$0.038 loss in FY 2023). Revenue: CA$123.0k (down 28% from FY 2023). Net loss: CA$1.40m (loss narrowed 55% from FY 2023).Board Change • Jan 26Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Tushar Arora was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Tushar Arora was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Jan 11Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.01 loss in 3Q 2023)Third quarter 2024 results: CA$0.001 loss per share (improved from CA$0.01 loss in 3Q 2023). Revenue: CA$26.7k (down 38% from 3Q 2023). Net loss: CA$104.4k (loss narrowed 89% from 3Q 2023).공시 • Jan 10Optimind Pharma Corp. Announces Executive ChangesOptimind Pharma Corp. announced that David Goodman, a member of the Company's Board of Directors, assumes the mantle of Chief Executive Officer ("CEO") with a forward-looking vision for Optimind's continued growth and innovation. Former CEO and Director, Tom Sipos, has gracefully stepped down due to personal reasons. The Company expresses gratitude to Mr. Sipos for his valuable contributions and extends best wishes for his future endeavors.Reported Earnings • Nov 01Second quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.01 loss in 2Q 2023)Second quarter 2024 results: CA$0.002 loss per share (improved from CA$0.01 loss in 2Q 2023). Revenue: CA$27.4k (down 36% from 2Q 2023). Net loss: CA$183.5k (loss narrowed 81% from 2Q 2023).Reported Earnings • Jul 30First quarter 2024 earnings releasedFirst quarter 2024 results: CA$0.004 loss per share. Net loss: CA$403.7k (flat on 1Q 2023).공시 • May 19Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023.공시 • Sep 21Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million.Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million on September 20, 2022. The acquisition was completed pursuant to an asset purchase agreement (the "APA") with Beatrice Society. Pursuant to the APA, the Company has issued a total of 22,500,000 common shares to the vendor which are subject to the following release terms: (i) 11,500,000 common shares are subject to a time release escrow as follows: (A) 5,343,750 are released on January 17, 2023; (B) 1,968,750 are released on March 17, 2023; (C) 1,968,750 are released on June 17, 2023; and, (D) (B) 1,968,750 are released on September 17, 2023; and (ii) 11,500,000 common shares are subject to earn-out milestones as follows: (A) 2,812,500 common shares; (B) 5,625,000 common shares; and (C) 2,812,500 common shares, with each of three earn-out milestones related to continued development of the protocols and courses for the acquired assets and intellectual property. Optimind Pharma Corp. (CNSX:OMND) completed the acquisition of MindSetting Inc. from Beatrice Society Inc. on September 20, 2022.매출 및 비용 세부 내역Optimind Pharma가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이CNSX:OMND 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Aug 25000031 May 25000028 Feb 25000030 Nov 240-10031 Aug 240-10031 May 240-11029 Feb 240-11030 Nov 230-31031 Aug 230-31031 May 230-31028 Feb 230-31028 Feb 220000양질의 수익: OMND 은(는) 현재 수익성이 없습니다.이익 마진 증가: OMND는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: OMND는 수익성이 없지만 지난 5년 동안 연평균 45.5%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 OMND의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: OMND은 수익성이 없어 지난 해 수익 성장률을 Healthcare 업계(-11.9%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: OMND의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/12/09 09:12종가2025/09/11 00:00수익2025/08/31연간 수익2025/02/28데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Optimind Pharma Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Jul 31First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$35.7k (up 123% from 1Q 2025). Net loss: CA$294 (loss narrowed 100% from 1Q 2025).
Reported Earnings • Jun 30Full year 2025 earnings released: CA$0.002 loss per share (vs CA$0.014 loss in FY 2024)Full year 2025 results: CA$0.002 loss per share (improved from CA$0.014 loss in FY 2024). Revenue: CA$118.4k (down 3.7% from FY 2024). Net loss: CA$215.8k (loss narrowed 85% from FY 2024).
Reported Earnings • Jan 31Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: EPS: CA$0 (improved from CA$0.001 loss in 3Q 2024). Revenue: CA$26.6k (flat on 3Q 2024). Net loss: CA$9.0k (loss narrowed 91% from 3Q 2024).
Reported Earnings • Nov 01Second quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 2Q 2024)Second quarter 2025 results: CA$0.001 loss per share (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$41.1k (up 50% from 2Q 2024). Net loss: CA$82.6k (loss narrowed 55% from 2Q 2024).
Reported Earnings • Aug 01First quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 1Q 2024)First quarter 2025 results: CA$0.001 loss per share (improved from CA$0.004 loss in 1Q 2024). Revenue: CA$16.0k (down 61% from 1Q 2024). Net loss: CA$97.5k (loss narrowed 76% from 1Q 2024).
Reported Earnings • Jul 01Full year 2024 earnings released: CA$0.014 loss per share (vs CA$0.038 loss in FY 2023)Full year 2024 results: CA$0.014 loss per share (improved from CA$0.038 loss in FY 2023). Revenue: CA$123.0k (down 28% from FY 2023). Net loss: CA$1.40m (loss narrowed 55% from FY 2023).
공시 • Sep 09Optimind Pharma Corp. announced that it expects to receive CAD 1.2 million in fundingOptimind Pharma Corp announced a private placement to issue 12,000,000 subscription receipts at an issue price of CAD 0.10 for the proceeds of CAD 1,200,000 on September 8, 2025. Finder's fees may be paid.
Reported Earnings • Jul 31First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$35.7k (up 123% from 1Q 2025). Net loss: CA$294 (loss narrowed 100% from 1Q 2025).
New Risk • Jul 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$310k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$310k free cash flow). Shares are highly illiquid. Negative equity (-CA$69k). Revenue is less than US$1m (CA$138k revenue, or US$100k). Market cap is less than US$10m (CA$515.7k market cap, or US$372.5k).
Reported Earnings • Jun 30Full year 2025 earnings released: CA$0.002 loss per share (vs CA$0.014 loss in FY 2024)Full year 2025 results: CA$0.002 loss per share (improved from CA$0.014 loss in FY 2024). Revenue: CA$118.4k (down 3.7% from FY 2024). Net loss: CA$215.8k (loss narrowed 85% from FY 2024).
Reported Earnings • Jan 31Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: EPS: CA$0 (improved from CA$0.001 loss in 3Q 2024). Revenue: CA$26.6k (flat on 3Q 2024). Net loss: CA$9.0k (loss narrowed 91% from 3Q 2024).
Reported Earnings • Nov 01Second quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 2Q 2024)Second quarter 2025 results: CA$0.001 loss per share (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$41.1k (up 50% from 2Q 2024). Net loss: CA$82.6k (loss narrowed 55% from 2Q 2024).
Reported Earnings • Aug 01First quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 1Q 2024)First quarter 2025 results: CA$0.001 loss per share (improved from CA$0.004 loss in 1Q 2024). Revenue: CA$16.0k (down 61% from 1Q 2024). Net loss: CA$97.5k (loss narrowed 76% from 1Q 2024).
공시 • Jul 05Optimind Pharma Corp. announced that it expects to receive CAD 0.5 million in fundingOptimind Pharma Corp. announced a private placement to issue 10,000,000 common shares at a price of CAD 0.05 per share for gross proceeds of up to CAD 500,000 on July 3, 2024. All securities issued in connection with the private placement will be subject to a statutory hold period expiring four months and one day from the date of issuance of the securities.
Reported Earnings • Jul 01Full year 2024 earnings released: CA$0.014 loss per share (vs CA$0.038 loss in FY 2023)Full year 2024 results: CA$0.014 loss per share (improved from CA$0.038 loss in FY 2023). Revenue: CA$123.0k (down 28% from FY 2023). Net loss: CA$1.40m (loss narrowed 55% from FY 2023).
Board Change • Jan 26Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Tushar Arora was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Tushar Arora was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jan 11Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.01 loss in 3Q 2023)Third quarter 2024 results: CA$0.001 loss per share (improved from CA$0.01 loss in 3Q 2023). Revenue: CA$26.7k (down 38% from 3Q 2023). Net loss: CA$104.4k (loss narrowed 89% from 3Q 2023).
공시 • Jan 10Optimind Pharma Corp. Announces Executive ChangesOptimind Pharma Corp. announced that David Goodman, a member of the Company's Board of Directors, assumes the mantle of Chief Executive Officer ("CEO") with a forward-looking vision for Optimind's continued growth and innovation. Former CEO and Director, Tom Sipos, has gracefully stepped down due to personal reasons. The Company expresses gratitude to Mr. Sipos for his valuable contributions and extends best wishes for his future endeavors.
Reported Earnings • Nov 01Second quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.01 loss in 2Q 2023)Second quarter 2024 results: CA$0.002 loss per share (improved from CA$0.01 loss in 2Q 2023). Revenue: CA$27.4k (down 36% from 2Q 2023). Net loss: CA$183.5k (loss narrowed 81% from 2Q 2023).
Reported Earnings • Jul 30First quarter 2024 earnings releasedFirst quarter 2024 results: CA$0.004 loss per share. Net loss: CA$403.7k (flat on 1Q 2023).
공시 • May 19Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023.
공시 • Sep 21Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million.Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million on September 20, 2022. The acquisition was completed pursuant to an asset purchase agreement (the "APA") with Beatrice Society. Pursuant to the APA, the Company has issued a total of 22,500,000 common shares to the vendor which are subject to the following release terms: (i) 11,500,000 common shares are subject to a time release escrow as follows: (A) 5,343,750 are released on January 17, 2023; (B) 1,968,750 are released on March 17, 2023; (C) 1,968,750 are released on June 17, 2023; and, (D) (B) 1,968,750 are released on September 17, 2023; and (ii) 11,500,000 common shares are subject to earn-out milestones as follows: (A) 2,812,500 common shares; (B) 5,625,000 common shares; and (C) 2,812,500 common shares, with each of three earn-out milestones related to continued development of the protocols and courses for the acquired assets and intellectual property. Optimind Pharma Corp. (CNSX:OMND) completed the acquisition of MindSetting Inc. from Beatrice Society Inc. on September 20, 2022.